Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in GermanyCompleted
NCT05305664Phase 3Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Hyperlipoproteinemia(a)
Germany
Phase IIIb Study of Ribociclib + ET in Early Breast CancerRecruiting
NCT05827081Phase 3Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Early Breast Cancer
United States, Argentina, Australia, Brazil, Canada +11 more
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Active Not Recruiting
NCT04603495Phase 3Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Myelofibrosis · Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
United States, Australia, Austria, Belgium, Canada +17 more
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.Active Not Recruiting
NCT05109728Phase 1Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Glioblastoma
United States, France, Portugal, Spain, Switzerland
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabActive Not Recruiting
NCT05142696Phase 1, Phase 2Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Extensive Stage Small Cell Lung Cancer
United States, Austria, Canada, China, Czechia +7 more
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabRecruiting
NCT07039422Phase 2Updated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Primary Immune Thrombocytopenia · Warm Autoimmune Hemolytic Anemia
Argentina, Belgium, China, Czechia, France +9 more
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerRecruiting
NCT07085767Phase 3Updated Jul 17, 2026
Sponsor: Olema Pharmaceuticals, Inc.
Breast Cancer · Locally Advanced Breast Cancer · Metastatic Breast Cancer · ER Positive Breast Cancer
United States, Australia, Austria, Belgium, Canada +17 more
A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer PatientsActive Not Recruiting
NCT07710716N/AUpdated Jul 17, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Switzerland
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineActive Not Recruiting
NCT03836040Phase 3Updated Jul 16, 2026
Sponsor: Amgen
Migraine
United States, Belgium, Canada, Colombia, Finland +11 more
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide TetraxetanRecruiting
NCT07677267N/AUpdated Jul 16, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant
United States
Modifying PEST for Psoriatic Arthritis ScreeningRecruiting
NCT06382051NAUpdated Jul 16, 2026
Sponsor: Novartis Pharmaceuticals
Plaque Psoriasis · Psoriatic Arthritis
Canada
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialActive Not Recruiting
NCT01217931Phase 2Updated Jul 16, 2026
Sponsor: M.D. Anderson Cancer Center
Kidney Cancer
United States
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibCompleted
NCT00756509Phase 4Updated Jul 16, 2026
Sponsor: Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
Finland, France, Germany, Italy, Spain
A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate CancerRecruiting
NCT07677254N/AUpdated Jul 16, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant
United States
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruiting
NCT05467891Phase 2Updated Jul 16, 2026
Sponsor: Oana Danciu
Locoregional Recurrence · Hormone Receptor-positive Breast Cancer · HER2-negative Breast Cancer
United States
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and AlirocumabRecruiting
NCT07543731N/AUpdated Jul 15, 2026
Sponsor: Novartis Pharmaceuticals
Cardiovascular Diseases · Atherosclerotic Cardiovascular Disease · Hypercholesterolemia, Familial
Switzerland
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney DiseaseRecruiting
NCT07235059Phase 1Updated Jul 15, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Kidney Disease
United States, Germany
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With AsthmaRecruiting
NCT05222529Phase 2Updated Jul 15, 2026
Sponsor: Novartis Pharmaceuticals
Asthma
Bulgaria, Colombia, Guatemala, Hungary, Poland +3 more
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic UrticariaRecruiting
NCT06865651Phase 2Updated Jul 15, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
United States, France, Germany, Poland, Spain
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSRecruiting
NCT07665437Phase 3Updated Jul 15, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
Argentina, Australia
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue FeverRecruiting
NCT06006559Phase 2Updated Jul 15, 2026
Sponsor: Novartis Pharmaceuticals
Dengue
Brazil, Colombia, India, Malaysia, Singapore +1 more
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)Recruiting
NCT07421167Phase 2Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP) · Primary Evans Syndrome (ES)
United States
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVDRecruiting
NCT06813911Phase 3Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD)
United States, China, France, Germany, Hong Kong +6 more
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGNRecruiting
NCT03955445Phase 3Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
C3 Glomerulopathy · Immune-complex-membranoproliferative Glomerulonephritis
United States, Argentina, Brazil, Canada, China +12 more
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsRecruiting
NCT07468071Phase 1, Phase 2Updated Jul 14, 2026
Sponsor: Novartis Pharmaceuticals
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer · Advanced Solid Tumors Harboring the KRAS G12C Mutation
Belgium, Canada, China, Japan, Malaysia +1 more

Previous page Next page